{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022791","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.390818+00:00","generated_at":"2026-05-17T16:46:54.344651+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M","bullets":["Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.","Cash $5.3M at June 30, 2025, down from $9.6M at Dec 31, 2024; restricted cash $0.1M.","FDA Fast Track Designation granted for CLD-201 for soft tissue sarcoma; Phase 1 IND opened Q1 2025.","Raised $4.6M gross proceeds via warrant inducement; total 2025 raises $15.7M.","Preclinical data for CLD-401 (RedTail platform) presented at ASCO; IND expected by end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022791","json":"https://secwatch.observer/filing/0001641172-25-022791.json","markdown":"https://secwatch.observer/filing/0001641172-25-022791.md","text":"https://secwatch.observer/filing/0001641172-25-022791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/0001641172-25-022791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:46:54.344651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}